Soho Flordis International (SFI)
Bioggio, Switzerland (ots) - Pharmaton and Soho Flordis International (SFI), an international provider of clinically proven natural medicines, announced today the acquisition of Ginsana SA, a leader and innovator in natural medicine products. The acquisition from Pharmaton, a company of the Boehringer Ingelheim ...
München (ots) - New data from the SEVITENSION study show the fixed-dose combination treatment Sevikar® (olmesartan/amlodipine) to be superior to perindopril in combination with amlodipine in reducing central blood pressure When the traditional arm (brachial) method of measurement is used, blood pressure is usually found to be higher than it is in the large central ...
Lugano, Switzerland & Copenhagen, Denmark (ots) - The decision follows promising findings from a Phase IIa Proof-of-Concept study. Helsinn is planning a Phase IIb study with elsiglutide, and study activities are expected to start in H2 2013. The Swiss pharmaceutical group Helsinn, a leading player in the cancer ...
Aachen (ots) - Healthcare professionals who would like to know more about the topical treatment of postherpetic neuralgia (PHN) can now find useful information online. PHN is a chronic disabling pain condition with symptoms often described as burning, stabbing, or shooting pain, and caused by a previous herpes zoster infection (commonly known as shingles). The new ...
Munich, Germany (ots) - * Lack of patient adherence to hypertension treatment is one of the root causes of failure to reach blood pressure goals, contributing to increased risk of serious cardiovascular events * The Daiichi Sankyo myHypertensionCare patient support programme aims to improve patient engagement and ...
Lugano/Glattbrugg, Switzerland (ots) - Helsinn Healthcare SA and Vifor Pharma, announced that the companies have entered into an exclusive license and distribution agreement for netupitant-palonosetron fixed dose combination, a Helsinn product currently in the development stage for the treatment of ...
The International Osteoporosis Foundation (IOF)
Rome, Italy (ots) - Every year 43,000 people die following osteoporotic fractures; reports show that European healthcare systems are not treating people at risk; burden and costs will rise dramatically by 2025. Two landmark multi-stakeholder reports launched today - Osteoporosis in the European Union and the Scorecard for Osteoporosis in Europe - describe and compare the epidemiology, burden, and management of ...
Norderstedt (ots) - Endomagnetics, the company developing a portfolio of products to improve the standard of breast cancer management, has announced it has signed a distribution agreement with Sysmex Europe GmbH, a subsidiary of global healthcare company Sysmex Corporation. Sysmex has the exclusive right to provide sales and support for Endomagnetics' SentiMag® system across the EMEA region. This is Endomagnetics' first ...
Schlieren-Zurich (ots) - The European Food Safety Authority (EFSA) has reviewed field performance data of the BOVIGAM® Interferon-y (IFN-y) test and recommends IFN-y tests for inclusion in the official list of stand-alone tests for bovine tuberculosis (TB). BOVIGAM® is currently widely used as a supplementary test to complement skin testing. Prionics trusts that the ...
Lugano, Switzerland (ots) - The Swiss pharmaceutical Helsinn Group announces today that Taiho Pharmaceutical Co. Ltd., Japanese licensee of Helsinn's second generation 5-HT3 receptor antagonist (5- HT3 RA) palonosetron, has launched on the national market the 0.75mg infusion bag formulation of palonosetron hydrochloride (Aloxi®). The infusion bag is an additional formulation to the 0.75mg injectable form already marketed ...
Lugano, Switzerland (ots) - ESASO, the European School for Advanced Studies in Ophthalmology, has opened the 12th AMD and Retina Congress in Prague. Following on from the 11th congress in Lisbon, which covered the whole spectrum of retinopathy, this year's meeting in the Czech Republic takes a significant step ...
Zurich, Switzerland (ots) - Sequana Medical is pleased to announce that it has received CE mark approval for use of its alfapump® system in patients with ascites caused by cancer (malignant ascites). The alfapump® system was first introduced to the European market last year for patients with refractory ascites ...
Zug (ots) - AmVac AG has announced that it has made decisive progress in the development of their new RSV vaccine. The vaccine candidate is based on AmVac's innovative Sendai virus vector platform and developed for the prevention of respiratory infections, which are induced by RSV (respiratory syncytial virus). RSV ...
Roggwil, Switzerland (ots) - Colds and flu are the most frequent illnesses experienced by the Western world. They lead to tremendous costs to public health and the economy, being the leading cause of absences from work and school. This is especially the case during the autumn and winter months when almost everyone suffers colds or flu a few times. Immune resistance ...
ITG Isotope Technologies Garching GmbH
Garching (ots) - ITG Isotope Technologies Garching GmbH (ITG) - specialist in innovative radioisotopes - expands its nuclear reactor and technology network in line with its strategy to guarantee global security of supply. In May 2012, ITG - a fully-owned subsidiary of ITM Isotopen Technologien München AG (ITM) based in Germany - and NTP Radioisotopes SOC Ltd (NTP) - a ...
Bern, Switzerland (ots) - - - Quality of Life (QoL) is strongly diminished in RVVC patients - Current available treatment fails in two thirds of patients - High medical need demands novel effective treatment options Pevion Biotech AG today announced results from a large, international survey on the Quality of Life ...
Hitachi Medical Systems Europe Holding AG
Zug, Switzerland (ots) - - - First ECR presentation of the combined Hitachi and Aloka ultrasound portfolio with its many highlights - New upgrades for ProSound F75 - New ergonomic lightweight ultrasound system F37 - Image fusion with Hitachi Real-time Virtual Sonography - A new era in MR imaging: the Echelon Oval ...
TRON - Translational Oncology at University Medical Center Mainz
Mainz (ots) - The Institute of Translational Oncology (TRON) together with BioNTech AG today announced the publication of a joint paper in the international journal Cancer Research that describes a new path for individually tailored cancer therapy. An interdisciplinary team of genome scientists and immunologists led ...
Ittigen, Switzerland (ots) - Pevion Biotech AG today announced further data from the ongoing clinical study of its therapeutic Candida vaccine PEV7, demonstrating the generation of specific and functional B cell memory in 100% of vaccinees. Furthermore, the results again confirm the capability of Pevion's second generation virosomal vaccine platform to induce strong ...
San Diego, CA, USA (ots) - Breadth of Pharmacokinetic Data Points to Tunable Half-life for Platform Pieris AG presented novel preclinical in vitro and in vivo data for its PRS-080 Anticalin hepcidin antagonist in an oral presentation at the American Society of Hematology Annual Meeting, the company announced today. ...
San Francisco, California (ots) - --Results Establish Safety, Tolerability, Lack of Immunogenicity and PK/PD Profile for First Anticalin in a Clinical Setting-- Pieris AG presented the results of the Company?s first clinical evaluation of its most advanced Anticalin®, PRS-050, an anti-VEGF targeted protein ...
Hilden, Germany, and Gaithersburg, Md. (ots) - Vaginal self-collection for Hybrid Capture®-based HPV testing increases screening coverage and is more sensitive than Pap smear shows a Mexican study published today online in the Lancet Promising findings published today online in the Lancet[i] from a community- based, randomized equivalence trial undertaken by public ...
Zejtun, Malta (ots) - "We know Libya is faced with shortages of essential supplies. That's why Actavis donates EUR 2M worth of medicines to Libya now. The goods will leave Malta on Sunday and arrive in Tripoli during next week", said Actavis CEO Claudio Albrecht. "Actavis is one of the world's largest generic pharmaceutical players and takes its social responsibility very seriously." Mr. Albrecht emphasized the role of ...
EUROSPINE, the Spine Society of Europe
Milan, Italy (ots) - The European congress for spine therapy, -surgery and orthopaedics will take place in Milan, Italy from 19-21 October and will attract numerous medical experts and industry specialists from around the globe. Thousands of participants will exchange their profound knowledge about latest research ...
Lugano, Switzerland and Greifswald, Germany (ots) - Helsinn Healthcare SA, Switzerland and Riemser Arzneimittel AG, German licensee of Helsinn's second generation 5-HT3 receptor antagonist palonosetron, announce today the signing of a licensing agreement granting Riemser the commercialization rights for a ...
St. Gallen, Switzerland (ots) - ForaCare Suisse AG located in St. Gallen, Switzerland announced today the launch of a Bluetooth enabled innovative, smart single-unit devices for combined blood glucose and blood pressure (BP) monitoring. One device, the Comfort Pro GD 40, is approved for use by medical professionals and the other, Duo Ultima D40b, is being made ...
Lugano, Switerland (ots) - The Company has entered the Phase III clinical program for both its investigational medications anamorelin, in non-small cell lung cancer-associated anorexia/cachexia, and netupitant + palonosetron oral fixed-dose combination in chemotherapy-induced nausea and vomiting (CINV) Helsinn, the Swiss pharmaceutical Group, global leader in the segment of the prevention of chemotherapy-induced nausea ...
Lugano, Switzerland and Woodcliff Lake, NJ, USA (ots) - Helsinn Group and Eisai Inc. announced today that Helsinn has commenced a multi-centered Phase III clinical study program investigating the Netupitant/Palonosetron (300mg/0.50mg) oral fixed-dose combination for the prevention of chemotherapy-induced nausea and ...
Amsterdam, The Netherlands (ots) - New data presented at the 14th World Conference on Lung Cancer in Amsterdam, The Netherlands, show the efficacy of the 2nd generation 5-HT3 receptor antagonist alone and in combination with aprepitant New data on the 2nd generation 5-HT3 receptor antagonist palonosetron, in the ...
European Renal Association - European Dialysis and Transplant Association (ERA-EDTA)
Prague (ots) - The SHARP-study has shown that lowering LDL cholesterol with ezetimibe/simvastatin leads to a significant reduction in major atherosclerotic events among CKD-patients. Whether it also has a favourable effect on renal disease progression was another of the issues addressed by the SHARP study [abstract ...